Pharma
Glenmark Pharmaceuticals Ltd
GLENMARK · NSE · INE935A01035Thursday, 10 Sept 202611:31 am
Market Cap—
P/E—
P/B—
EPS—
Div Yield—
ROE23.6%
ROCE39.8%
ROE23.6%
1Y Return+20.78%
Avg. Volume0.5M
Price Chart
52-Week Range
About
Glenmark Pharmaceuticals Ltd is a Pharma company listed on NSE.
Technicals
Free account
Register freeTechnicals
Create a free account to view momentum, moving averages, and delivery signals.
Quant
Premium
UpgradeQuant metrics
Upgrade to view volatility, drawdown, factor, and risk metrics.
Key Ratios
Market Cap—
Current Price₹2,425.6
52W High / Low₹2,537.6 / ₹1,792.6
Stock P/E—
Price to Book—
EPS (TTM)—
Dividend Yield—
ROE23.6%
1Y Return+20.78%
Day Change-0.57%
Profit & Loss
| Period | TTM | FY26 | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹17,737 Cr | ₹16,983 Cr | ₹13,322 Cr | ||||||||||
| Expenses | ₹12,940 Cr | ₹12,410 Cr | ₹10,970 Cr | ||||||||||
| Operating Profit | ₹4,797 Cr | ₹4,572 Cr | ₹2,351 Cr | ||||||||||
| OPM % | 27.0% | 27.0% | 18.0% | ||||||||||
| Other Income | ₹-1,443 Cr | ₹-1,805 Cr | ₹-259 Cr | ||||||||||
| Depreciation | ₹617 Cr | ₹573 Cr | ₹486 Cr | ||||||||||
| Interest | ₹204 Cr | ₹209 Cr | ₹207 Cr | ||||||||||
| Profit Before Tax | ₹2,533 Cr | ₹1,985 Cr | ₹1,399 Cr | ||||||||||
| Tax | ₹735 Cr | ₹623 Cr | ₹352 Cr | ||||||||||
| Net Profit | ₹1,798 Cr | ₹1,362 Cr | ₹1,047 Cr | ||||||||||
| EPS (₹) | 63.7 | 48.3 | 37.1 | ||||||||||
| Dividend Payout % | — | 10% | 7% |
Financial history locked
Register freeRegister free to see 10 more years.
Quarterly Results
| Quarter | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹4,018 Cr | ₹3,771 Cr | ₹3,901 Cr | ₹6,047 Cr | |||||||||
| Expenses | ₹3,214 Cr | ₹3,008 Cr | ₹3,031 Cr | ₹3,687 Cr | |||||||||
| Operating Profit | ₹805 Cr | ₹763 Cr | ₹870 Cr | ₹2,360 Cr | |||||||||
| OPM % | 20.0% | 20.0% | 22.0% | 39.0% | |||||||||
| Depreciation | ₹173 Cr | ₹148 Cr | ₹154 Cr | ₹141 Cr | |||||||||
| Interest | ₹54 Cr | ₹43 Cr | ₹41 Cr | ₹66 Cr | |||||||||
| Net Profit | ₹483 Cr | ₹301 Cr | ₹403 Cr | ₹610 Cr | |||||||||
| EPS (₹) | 17.1 | 10.7 | 14.3 | 21.6 |
Quarterly history locked
Register freeRegister free to see 9 more quarters.
Balance Sheet
| Period | FY26 | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity Capital | ₹28 Cr | ₹28 Cr | ₹28 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reserves | ₹10,484 Cr | ₹8,821 Cr | ₹7,820 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Borrowings | ₹594 Cr | ₹2,473 Cr | ₹1,231 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Liabilities | ₹8,801 Cr | ₹4,669 Cr | ₹5,279 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Liabilities | ₹19,907 Cr | ₹15,991 Cr | ₹14,358 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fixed Assets | ₹5,915 Cr | ₹4,487 Cr | ₹4,210 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investments | ₹42 Cr | ₹56 Cr | ₹790 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Receivables | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventory | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash & Equivalents | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Assets | ₹13,041 Cr | ₹10,613 Cr | ₹8,697 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Assets | ₹19,907 Cr | ₹15,991 Cr | ₹14,358 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance sheet history locked
Register freeRegister free to see 10 more years.
Cash Flow
| Period | Operating | Investing | Financing | Net Cash Flow |
|---|---|---|---|---|
| FY26 | ₹3,445 Cr | ₹-1,237 Cr | ₹-2,709 Cr | ₹-501 Cr |
| FY25 | ₹-828 Cr | ₹58 Cr | ₹787 Cr | ₹17 Cr |
| FY24 | ₹-265 Cr | ₹4,387 Cr | ₹-3,906 Cr | ₹215 Cr |
| FY23 | ||||
| FY22 | ||||
| FY21 | ||||
| FY20 | ||||
| FY19 | ||||
| FY18 | ||||
| FY17 | ||||
| FY16 | ||||
| FY15 |
Cash flow history locked
Register freeRegister free to see 10 more years.
Peer Comparison
| Company | M.Cap | P/E | ROE | 1Y Return |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | — | — | +14.78% | +7.18% |
| Dr Reddys Laboratories Ltd | — | — | +8.84% | -3.74% |
| Cipla Ltd | — | — | +11.77% | -5.50% |
| Apollo Hospitals Enterprise Ltd | — | — | +22.64% | +23.01% |
| Divis Laboratories Ltd | ₹2,50,065 Cr | 83.9 | +16.5% | +46.29% |
Mutual Fund Holdings
Free account
Register freeMutual fund holdings
Create a free account to see institutional ownership snapshots.
Bulk & Block Deals
Free account
Register freeBulk & block deals
Create a free account to view recent institutional deal activity.
Analyst Estimates
Free account
Register freeAnalyst estimates
Create a free account to view analyst estimate summaries.
Latest News
2026-09-10Glenmark Pharmaceuticals and South Piedmont Community College Launch Aseptic Training Facility in Monroe, N.C.PR Newswire2026-08-21Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseBSE Filing2026-08-03Glenmark Pharmaceuticals Ltd (BOM:532296) (Q1 2027) Earnings Call Highlights: Strong 23% ...GuruFocus.com2026-07-28Glenmark Pharmaceuticals Inc., USA launches Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose VialsPR Newswire2026-06-11Cosmo Welcomes the Launch of Winlevi(R) in Key European Markets by Its Partner GlenmarkTMX Newsfile
Documents & Filings
rupiya.io is for research and education only. Metrics shown are not investment advice. Validate with SEBI-regulated disclosures before acting.